275 related articles for article (PubMed ID: 22218796)
21. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
[TBL] [Abstract][Full Text] [Related]
22. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
23. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
24. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
Prucka SK; McIlvried DE; Korf BR
Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
[TBL] [Abstract][Full Text] [Related]
25. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
26. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
27. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
28. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
30. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
[TBL] [Abstract][Full Text] [Related]
31. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
Pepe C; Guidugli L; Sensi E; Aretini P; D'Andrea E; Montagna M; Manoukian S; Ottini L; Radice P; Viel A; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2007 May; 103(1):29-36. PubMed ID: 17151928
[TBL] [Abstract][Full Text] [Related]
32. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
Dombernowsky SL; Weischer M; Freiberg JJ; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2339-42. PubMed ID: 19661094
[TBL] [Abstract][Full Text] [Related]
33. The future of DNA diagnostics.
Critchfield GC
Dis Markers; 1999 Oct; 15(1-3):108-11. PubMed ID: 10595261
[No Abstract] [Full Text] [Related]
34. The role of BRCA mutation testing in determining breast cancer therapy.
Trainer AH; Lewis CR; Tucker K; Meiser B; Friedlander M; Ward RL
Nat Rev Clin Oncol; 2010 Dec; 7(12):708-17. PubMed ID: 21060331
[TBL] [Abstract][Full Text] [Related]
35. [Genetic predisposition to breast and ovarian cancer: importance of test results].
Julian-Reynier C
Med Sci (Paris); 2011; 27(6-7):657-61. PubMed ID: 21718651
[TBL] [Abstract][Full Text] [Related]
36. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
Møller P; Evans G; Haites N; Vasen H; Reis MM; Anderson E; Apold J; Hodgson S; Eccles D; Olsson H; Stoppa-Lyonnet D; Chang-Claude J; Morrison PJ; Bevilacqua G; Heimdal K; Maehle L; Lalloo F; Gregory H; Preece P; Borg A; Nevin NC; Caligo M; Steel CM
Dis Markers; 1999 Oct; 15(1-3):207-11. PubMed ID: 10595280
[TBL] [Abstract][Full Text] [Related]
37. Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
Pasini B; Pierotti MA
Dis Markers; 1999 Oct; 15(1-3):41-3. PubMed ID: 10595250
[No Abstract] [Full Text] [Related]
38. Genetic testing by cancer site: breast.
Shannon KM; Chittenden A
Cancer J; 2012; 18(4):310-9. PubMed ID: 22846731
[TBL] [Abstract][Full Text] [Related]
39. Costs and benefits of diagnosing familial breast cancer.
Heimdal K; Maehle L; Møller P
Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
[TBL] [Abstract][Full Text] [Related]
40. Lessons learned from genetic testing.
Esserman L; Kaklamani V
JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
